Financial Survey of Titan Medical (NASDAQ:TMDI) and Cytosorbents (NASDAQ:CTSO)


Titan Medical (NASDAQ:TMDI – Get Rating) and Cytosorbents (NASDAQ:CTSO – Get Rating) are both small-cap medical companies, but which is the better stock? We’ll compare the two companies based on valuation strength, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Titan Medical and Cytosorbents, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Medical Titan 0 1 1 0 2.50
Cytosorbents 0 0 4 0 3.00

Cytosorbents has a consensus price target of $9.67, indicating a potential upside of 292.95%. Given Cytosorbents’ higher consensus rating and higher upside potential, analysts clearly believe Cytosorbents is more favorable than Titan Medical.

Profitability

This table compares the net margins, return on equity and return on assets of Titan Medical and Cytosorbents.

Net margins Return on equity return on assets
Medical Titan N / A -79.35% -49.13%
Cytosorbents -71.16% -44.65% -32.08%

Benefits and evaluation

This table compares the revenue, earnings per share and valuation of Titan Medical and Cytosorbents.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Medical Titan $20.09 million 3.26 -$14.86 million ($0.09) -6.53
Cytosorbents $43.17 million 2.48 -$24.56 million ($0.68) -3.62

Titan Medical has higher revenue, but lower revenue than Cytosorbents. Titan Medical trades at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

3.7% of Titan Medical shares are held by institutional investors. In comparison, 41.0% of Cytosorbents shares are held by institutional investors. 7.0% of Cytosorbents shares are held by insiders. Strong institutional ownership indicates that large fund managers, endowments, and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Titan Medical has a beta of 2.62, which means its stock price is 162% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.37, which means its stock price is 63% less volatile than the S&P 500.

Summary

Cytosorbents beats Titan Medical on 9 out of 14 factors compared between the two stocks.

About Titan Medical (Get an evaluation)

Titan Medical Inc., a medical technology company, is focused on the development and commercialization of robot-assisted surgical technologies for application in minimally invasive surgery. It develops the Enos System, a single-access robotic surgical system that includes a surgeon-controlled patient cart featuring a high-definition 3D vision system and multi-articulated instruments to perform surgical procedures; and a surgeon workstation that provides the surgeon with an ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during surgical procedures. The company is headquartered in Toronto, Canada.

About cytosorbents (Get an evaluation)

Cytosorbents Corporation engages in the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. Its lead product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of surgery cardiopulmonary bypass, and maintaining or improving the quality of solid organs removed from donors. for organ transplant. The company is also developing VetResQ, an adjunctive therapy device in the treatment of sepsis, pancreatitis and other serious illnesses in animals; CytoSorb-XL, an adjunctive therapy device in the treatment of sepsis and other serious illnesses; HemoDefend blood purification technology platform for reducing contaminants in the blood supply that can cause transfusion reactions or illness when administering blood and blood products to patients, as well as eliminating anti-A antibodies and anti-B from whole blood and fresh plasma; K+ontrol for the treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for removal of IV contrast from blood administered during CT imaging, angiography or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, she is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients suffering from chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic elimination system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.



Receive news and reviews for Titan Medical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Titan Medical and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.